

Publikationsliste – Dr. Nicole Plank

11. Wydra, V. R., **Plank, N.**, Zwirner, S., Selig, R., Rasch, A., Masberg, B., Lämmerhofer, M., Zender, L., Koch, P., Albrecht, W., Laufer, S. A. “Ligand First” Approach toward Selective, Covalent JNK2/3 Inhibitors. *Journal of Medicinal Chemistry* **2025**, asap. <https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00884>
10. Hoffelner, B. S., Andreev, S., **Plank, N.**, Koch, P. Photocaging of Pyridinylimidazole-Based Covalent JNK3 Inhibitors Affords Spatiotemporal Control of the Binding Affinity in Live Cells. *Pharmaceuticals* **2023**, 16, 264.
9. Andreev, S., **Plank, N.**, Schollmeyer, D., Koch, P. (S)-3-(3-((7-Ethynyl-9H-pyrimido[4,5-b]indol-4-yl)amino)piperidin-1-yl)propanenitrile. *Molbank* **2022**, 2022, M1437.
8. Seibel-Ehlert, U., **Plank, N.**, Inoue, A., Bernhardt, G., Strasser, A. Label-Free Investigations on the G Protein Dependent Signaling Pathways of Histamine Receptors. *International Journal of Molecular Sciences* **2021**, 22, 1-33.
7. Tropmann, K., Höring, C., **Plank, N.**, Pockes, S. Discovery of a G Protein-Biased Radioligand for the Histamine H₂ Receptor with Reversible Binding Properties. *Journal of Medicinal Chemistry* **2020**, 63, 13090-13102.
6. Yang, Z., Han, S., Keller, M., Kaiser, A., Bender, B. J., Bosse, M., Burkert, K., Kögler, L. M., Wifling, D., Bernhardt, G., **Plank, N.**, Littmann, T., Schmidt, P., Yi, C., Li, B., Ye, S., Zhang, R., Xu, B., Larhammar, D., Stevens, R. C., Huster, D., Meiler, J., Zhao, Q., Beck-Sickinger, A. G., Buschauer, A. und Wu, B. Structural basis of ligand binding modes at the neuropeptide YY₁ receptor. *Nature* **2018**, 556, 520-524.
5. Lieb, S., Littmann, T., **Plank, N.**, Felixberger, J., Tanaka, M., Schäfer, T., Krief, S., Elz, S., Friedland, K., Bernhardt, G., Wegener, J., Ozawa, T., Buschauer, A. Label-free versus conventional cellular assays: functional investigations on the human histamine H₁ receptor. *Pharmacological Research* **2016**, 114, 13-26.
4. Lieb, S., Michaelis, S., **Plank, N.**, Bernhardt, G., Buschauer, A., Wegener, J. Label-free analysis of GPCR-stimulation: The critical impact of cell adhesion. *Pharmacological Research* **2016**, 108, 65-74.
3. Baumeister, P., Erdmann, D., Biselli, S., **Kagermeier, N.**, Elz, S., Bernhardt, G., Buschauer, A. ³HUR-DE257: Development of a tritium-labeled squaramide-type selective histamine H₂ receptor antagonist. *ChemMedChem* **2015**, 10, 83-93.
2. **Kagermeier, N.**, Werner, K., Keller, M., Baumeister, P., Bernhardt, G., Seifert, R., Buschauer, A. Dimeric carbamoylguanidine-type histamine H₂ receptor ligands: A new class of potent and selective agonists. *Bioorganic & Medicinal Chemistry* **2015**, 23, 3957-3969.

1. Birnkammer, T., Spickenreither, A., Brunskole, I., Lopuch, M., **Kagermeier, N.**, Bernhardt, G., Dove, S., Seifert, R., Elz, S., Buschauer, A. The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H₂ receptor agonists. *Journal of Medicinal Chemistry* **2015**, 55, 1147-1160.